Meet Samuel – Your Personal Investing Prophet
Jupiter Neurosciences, Inc. ( (JUNS) ) has provided an update.
On May 20, 2026, Jupiter Neurosciences, Inc. entered into a securities purchase agreement for a registered direct offering of 7,142,858 shares of common stock at $0.28 per share, for gross proceeds of about $2.0 million, under an effective shelf registration statement. The company agreed to a 30-day restriction on issuing additional common stock or equivalents following closing, which is expected on or about May 21, 2026, placing near-term limits on equity issuance but bolstering liquidity for its CNS-focused pipeline.
Jupiter engaged D. Boral Capital LLC as exclusive placement agent under a separate agreement, agreeing to pay a 7.0% cash fee on gross proceeds and reimburse certain expenses, reinforcing the company’s access to capital markets despite associated dilution and transaction costs. The transaction follows SEC effectiveness of the Form S-3 registration on April 24, 2026, supporting ongoing funding for its clinical and commercial programs in a competitive neuro-focused biopharma landscape.
The most recent analyst rating on (JUNS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Jupiter Neurosciences, Inc. stock, see the JUNS Stock Forecast page.
More about Jupiter Neurosciences, Inc.
Jupiter Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation. Its pipeline includes lead candidate JOTROL, an enhanced bioavailability resveratrol formulation in a Phase IIa Parkinson’s disease trial, and it also commercializes the consumer longevity supplement Nugevia and holds U.S. rights to the psychedelic NCE ALA-002.
Average Trading Volume: 3,878,662
Technical Sentiment Signal: Sell
Current Market Cap: $7.44M
For an in-depth examination of JUNS stock, go to TipRanks’ Overview page.